InsiderTrades.com logo
Amazon's $150B Data Center Bet—What It Means for Uranium Investors
From The Bull Report   |   Ad
Amazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up.
Read More to Learn How You Can Position Yourself for the Next Uranium Boom
Susan Altschuller net worth and biography
  • Phone
  • Email
  • Website

Susan Altschuller Biography and Net Worth

Sr. VP & CFO of ImmunoGen
Dr. Altschuller has 20 years of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. She joins ImmunoGen from Alexion Pharmaceuticals where she started as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company’s strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She received a BSE in Biomedical Engineering with Honors from Tulane University, a PhD in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management.

How do I contact Susan Altschuller?

The corporate mailing address for Dr. Altschuller and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at [email protected]. Learn More on Susan Altschuller's contact information.

Has Susan Altschuller been buying or selling shares of ImmunoGen?

Susan Altschuller has not been actively trading shares of ImmunoGen in the last ninety days. Learn More on Susan Altschuller's trading history.

Who are ImmunoGen's active insiders?

ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (President, CEO & Director), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Are insiders buying or selling shares of ImmunoGen?

During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 338,452 shares worth more than $9,901,225.12. The most recent insider tranaction occured on January, 16th when SVP Theresa Wingrove sold 187,667 shares worth more than $5,562,449.88. Insiders at ImmunoGen own 5.1% of the company. Learn More about insider trades at ImmunoGen.

Information on this page was last updated on 1/16/2024.

Susan Altschuller Insider Trading History at ImmunoGen

See Full Table

Susan Altschuller Buying and Selling Activity at ImmunoGen

This chart shows Ms. Susan Altschuller's buying and selling at ImmunoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmunoGen Company Overview

ImmunoGen logo
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
Read More

Today's Range

Now: $31.23
Low: $31.23
High: $31.23

50 Day Range

MA: $31.23
Low: $31.23
High: $31.23

2 Week Range

Now: $31.23
Low: $3.61
High: $31.25

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18
Amazon's $150B Data Center Bet—What It Means for Uranium Investors
From The Bull Report   |   Ad
Amazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With demand for electricity skyrocketing from data centers, AI, and emerging tech, Amazon recognizes nuclear power as the only viable solution to meet its needs sustainably and at scale. But here's the critical catch: nuclear power requires uranium, and the global supply is struggling to keep up.
Read More to Learn How You Can Position Yourself for the Next Uranium Boom